JP2021504468A5 - - Google Patents
Info
- Publication number
- JP2021504468A5 JP2021504468A5 JP2020545883A JP2020545883A JP2021504468A5 JP 2021504468 A5 JP2021504468 A5 JP 2021504468A5 JP 2020545883 A JP2020545883 A JP 2020545883A JP 2020545883 A JP2020545883 A JP 2020545883A JP 2021504468 A5 JP2021504468 A5 JP 2021504468A5
- Authority
- JP
- Japan
- Prior art keywords
- propylene glycol
- glycerol
- pharmaceutical preparation
- hydroxyandrostan
- preparation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762590757P | 2017-11-27 | 2017-11-27 | |
| US62/590,757 | 2017-11-27 | ||
| PCT/EP2018/082727 WO2019102040A1 (en) | 2017-11-27 | 2018-11-27 | PHARMACEUTICAL FORMULATION OF 3α-ETHYNYL-3β-HYDROXYANDROSTAN-17-ONE OXIME |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021504468A JP2021504468A (ja) | 2021-02-15 |
| JP2021504468A5 true JP2021504468A5 (enExample) | 2023-03-30 |
| JP7314459B2 JP7314459B2 (ja) | 2023-07-26 |
Family
ID=64556898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020545883A Active JP7314459B2 (ja) | 2017-11-27 | 2018-11-27 | ３α－エチニル－３β－ヒドロキシアンドロスタン－１７－オンオキシムの医薬製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10603326B2 (enExample) |
| EP (1) | EP3716954A1 (enExample) |
| JP (1) | JP7314459B2 (enExample) |
| KR (1) | KR102771577B1 (enExample) |
| CN (1) | CN111432805B (enExample) |
| AU (1) | AU2018374029B2 (enExample) |
| BR (1) | BR112020010519A2 (enExample) |
| CA (1) | CA3083555A1 (enExample) |
| IL (1) | IL274893B2 (enExample) |
| MX (1) | MX391097B (enExample) |
| UA (1) | UA128186C2 (enExample) |
| WO (1) | WO2019102040A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA128186C2 (uk) | 2017-11-27 | 2024-05-01 | Умекрайн Когнішн Аб | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 3<font face="Symbol">a</font>-ЕТИНІЛ-3<font face="Symbol">b</font>-ГІДРОКСІАНДРОСТАН-17-ОНУ ОКСИМУ |
| EP4079307A1 (en) * | 2021-04-20 | 2022-10-26 | Umecrine Cognition AB | New medical use |
| EP4389129A1 (en) | 2022-12-22 | 2024-06-26 | Umecrine Cognition AB | 3a-ethynyl-3beta hydroxyandrostan 17-one oxime for treating parkinson's disease and l-dopa-induced dyskinesia |
| WO2025252725A1 (en) | 2024-06-04 | 2025-12-11 | Umecrine Cognition Ab | Novel pharmaceutical formulation of golexanolone |
| WO2025252724A1 (en) | 2024-06-04 | 2025-12-11 | Umecrine Cognition Ab | Novel pharmaceutical formulation of golexanolone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| GB9608719D0 (en) | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
| SE511313C2 (sv) | 1997-01-13 | 1999-09-06 | Gs Dev Ab | Komposition med reglerad frisättning innefattande fettsyraester av diacylglycerol |
| GB9907715D0 (en) | 1999-04-01 | 1999-05-26 | Scherer Corp R P | Pharmaceutical compositions |
| KR20010100194A (ko) * | 2000-03-13 | 2001-11-14 | 박호군 | 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법 |
| US20040191207A1 (en) | 2003-03-31 | 2004-09-30 | Lipari John M. | Alpha-hydroxy acid ester drug delivery compositions and methods of use |
| JP2010502703A (ja) | 2006-09-06 | 2010-01-28 | メルク エンド カムパニー インコーポレーテッド | 置換アミドの経口投与のための液体及び半固体の医薬製剤 |
| EP2711372A1 (en) | 2006-11-21 | 2014-03-26 | Umecrine AB | The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of CNS disorders |
| JP5687287B2 (ja) | 2010-01-14 | 2015-03-18 | ウメクライン ムード エービー | 改善された保存性及び溶解特性を有する３−ベータ−ヒドロキシ−５−アルファ−プレグナン−２０−オンを含有する薬学的組成物 |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US8951996B2 (en) | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
| US9801819B2 (en) | 2012-06-28 | 2017-10-31 | Johnson & Johnson Consumer Inc. | Racecadotril compositions |
| HK1223300A1 (zh) | 2013-06-03 | 2017-07-28 | Tolmar, Inc. | 皮质类固醇组合物 |
| CN106163528A (zh) * | 2014-01-29 | 2016-11-23 | 梅克芳识别有限公司 | 用于治疗肝脑病的甾族化合物 |
| WO2015193224A1 (en) | 2014-06-17 | 2015-12-23 | Merck Sharp & Dohme B.V. | Stable formulations of testosterone undecanoate |
| US9498485B2 (en) * | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| KR101679992B1 (ko) | 2015-12-31 | 2016-11-28 | 주식회사 유유제약 | 프로필렌글리콜 모노라우레이트를 포함하는 두타스테리드의 약학적 조성물 및 이의 제조 방법 |
| KR101716878B1 (ko) | 2016-05-12 | 2017-03-15 | 주식회사 유유제약 | 글리세롤 지방산에스테르유도체 또는 프로필렌글리콜 지방산에스테르유도체를 함유한 두타스테리드와 타다라필의 복합 캡슐제제 조성물 및 이의 제조방법 |
| US10278977B2 (en) | 2016-06-06 | 2019-05-07 | Umecrine Cognition Ab | Methods for treating hypersomnolence |
| UA128186C2 (uk) | 2017-11-27 | 2024-05-01 | Умекрайн Когнішн Аб | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ 3<font face="Symbol">a</font>-ЕТИНІЛ-3<font face="Symbol">b</font>-ГІДРОКСІАНДРОСТАН-17-ОНУ ОКСИМУ |
-
2018
- 2018-11-27 UA UAA202003834A patent/UA128186C2/uk unknown
- 2018-11-27 EP EP18811225.4A patent/EP3716954A1/en active Pending
- 2018-11-27 JP JP2020545883A patent/JP7314459B2/ja active Active
- 2018-11-27 IL IL274893A patent/IL274893B2/en unknown
- 2018-11-27 BR BR112020010519-8A patent/BR112020010519A2/pt active Search and Examination
- 2018-11-27 CN CN201880076423.8A patent/CN111432805B/zh active Active
- 2018-11-27 CA CA3083555A patent/CA3083555A1/en active Pending
- 2018-11-27 MX MX2020005442A patent/MX391097B/es unknown
- 2018-11-27 WO PCT/EP2018/082727 patent/WO2019102040A1/en not_active Ceased
- 2018-11-27 KR KR1020207018543A patent/KR102771577B1/ko active Active
- 2018-11-27 AU AU2018374029A patent/AU2018374029B2/en active Active
-
2019
- 2019-06-24 US US16/450,620 patent/US10603326B2/en active Active
-
2020
- 2020-02-21 US US16/797,426 patent/US11123351B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2207859C1 (ru) | Фармацевтические композиции для перорального применения, содержащие длинноцепочечные триглицериды и липофильные поверхностно-активные вещества | |
| JP2015520236A5 (enExample) | ||
| JPWO2022234850A5 (enExample) | ||
| JP2023015334A5 (enExample) | ||
| JP7314459B2 (ja) | ３α－エチニル－３β－ヒドロキシアンドロスタン－１７－オンオキシムの医薬製剤 | |
| CN112691078A (zh) | 含有紫杉烷的用于口服给药的药物组合物 | |
| JP6618488B2 (ja) | テストステロンウンデカノエートの安定な製剤 | |
| KR20140016926A (ko) | 활성제로서 페닐아미노피리미딘 유도체를 포함하는 제제 | |
| US10806742B2 (en) | Liquid phospholipid-containing compositions for the preparation of pharmaceuticals | |
| US10960016B2 (en) | Capsules containing high doses of krill phospholipids | |
| NZ764901B2 (en) | PHARMACEUTICAL FORMULATION OF 3a-ETHYNYL-3ß-HYDROXYANDROSTAN-17-ONE OXIME | |
| RU2779262C2 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ 3α-ЭТИНИЛ-3β-ГИДРОКСИАНДРОСТАН-17-ОНА ОКСИМА | |
| JPH10330250A (ja) | メナテトレノン油性製剤 | |
| US20190247308A1 (en) | Stable liquid formulations | |
| HK40041450A (en) | Pharmaceutical composition for oral administration comprising taxane | |
| EP3768322A1 (en) | Formulation |